glp-1 drugs and alzheimer's Can popular diabetes weight-loss slow vascular dementia? GLP-1 drugs failed to slow

The FDA in early 2026 highlighted enforcement actions targeting non-approved GLP-1 active ingredients in compounded drugs, which underscores the quality-control concern

The drug, melanotan II, is banned as a cosmetic product in the United States, the United Kingdom, Australia, Denmark, and other countries

Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies

Mechanism snapshot Positioned within NNMT inhibitor-class research for metabolic and methylation-linked pathways, distinct from NMN replacement biology

Not for treating diagnosed medical pigmentation disorders

Mild side effects may include redness, swelling, or pain at the injection site, as well as headache, dizziness, or nausea